Bringing over 25 years of software development experience to the team, Samuel Chen is the president and CEO of AIxMed. He was the Vice President of Software Development at Trend Micro and helped establish the company as one of the top three information security companies in the world and Taiwan’s #1 software company. Additionally, Mr. Chen held executive leadership roles at ASUSTek and Compal and founded the Compal AI Lab. Mr. Chen graduated from National Chiao-Tung University and attained a Master’s of Science degree in computer science from the University of Southern California.

Tien-Jen Liu, MD, is an experienced attending physician with a proven history in the biotechnology industry. Dr. Liu is skilled in clinical research, medical device development, clinical study, and business development. He is also the director of the biomedical innovation program at a medical university.

Steph Hess is an experienced business development professional bringing two decades of IVD and life science experience to the team in both Product and Business Development. He has consulted for dozens of start-up companies and helped introduce multiple products to the market. Mr. Hess was previously VP Global Business Development at Invetech and VP Global Sales and Marketing at IDEX Health and Science. Steph obtained an Engineering Degree from Rutgers University and a Master’s of Science degree in Management from WPI.

Dr. Crothers is both a highly decorated U.S. Army veteran and one of the country’s most renowned Cytopathologists. Prior to joining AIxMed, she served as Senior (Consultant) Pathologist at The Joint Pathology Center (JPC), known as the premier pathology reference center for the U.S. federal government. Dr. Crothers is board-certified in anatomic and clinical pathology as well as Cytopathology, and over the course of her career, she has received numerous professional, military, and academic honors and awards. She has served as President and Executive Board Member of the American Society of Cytopathology (ASC) and the Chair of the Cytopathology Committee at the College of American Pathologists (CAP).